AI Article Synopsis
- Recent research shows that unsuccessful cytogenetics (UC) in patients with acute myeloid leukaemia (AML) correlates with older age and poorer survival outcomes.
- In a study of 1,737 patients under 80, the rates of UC and unperformed cytogenetics (UPC) were found to be 2.1% and 20%, with early death rates highest in UC and UPC groups.
- Patients with UC and UPC had significantly lower remission rates and five-year survival (25% and 22%, respectively) compared to those with successfully karyotyped AML (up to 64%), indicating that missing cytogenetic data can severely impact patient prognosis.
Article Abstract
Unsuccessful cytogenetics (UC) in patients with acute myeloid leukaemia (AML) treated on different SWOG trials was recently reported to be associated with increased age and dismal outcome. To ascertain whether this holds true also in unselected patients with AML, we retrieved all cytogenetic reports in cases from the population-based Swedish AML Registry. Between 1997 and 2006, 1737 patients below 80 yr of age without myelosarcoma or acute promyelocytic leukaemia received intensive treatment. The frequencies of UC and unperformed cytogenetics (UPC) were 2.1% and 20%, respectively. The early death rates differed between the cytogenetic subgroups (P = 0.006) with the highest rates in patients with UC (14%) and UPC (12%) followed by high-risk (HR) AML, intermediate risk (IR) and standard risk (SR) cases successfully karyotyped (8.6%, 5.9%, and 5.8%, respectively). The complete remission rate was lower in UC and UPC and HR compared with the other risk groups (P < 0.001). The overall five-year survival rates were 25% for UC and 22% for UPC, whereas the corresponding frequencies for SR, IR and HR AML patients without UC and UPC were 64%, 31% and 15%, respectively. In conclusion, lack of cytogenetic data translates into a poor prognosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ejh.12446 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients.
Transplant Cell Ther
October 2024
Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, Montréal, Québec, Canada; Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.
Article Synopsis
- Multiple myeloma (MM) poses significant treatment challenges, particularly for high-risk patients, with allogeneic hematopoietic cell transplantation (HCT) often resulting in severe side effects and high mortality rates.
- This study investigates the safety and feasibility of using UM171-expanded cord blood transplantation combined with autologous HCT for patients with high-risk MM.
- Out of 20 enrolled patients, 19 successfully underwent the UM171 procedure, highlighting potential improvements in patient outcomes despite the historical issues associated with cord blood transplantation.
Establishment and characterization of novel spontaneously immortalized larval cell lines from sablefish Anoplopoma fimbria.
In Vitro Cell Dev Biol Anim
September 2024
Pacific Biological Station, Fisheries and Oceans Canada, Pacific Biological Station 3190 Hammond Bay Rd., Nanaimo, BC V9T6N7, Canada.
Article Synopsis
- Sablefish (Anoplopoma fimbria) is a valuable North Pacific groundfish that is sought for aquaculture to meet high market demand, but production faces challenges due to disease and limited health information.
- Research focused on creating immortalized larval cell lines from sablefish, resulting in six distinct sublines that exhibit two different cell morphologies.
- These cell lines have shown diploidy and robustness in growth under specific conditions, providing a vital resource for future studies on sablefish health and biology.
IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification.
Case Rep Hematol
June 2023
Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan.
IgE plasma cell neoplasm is the rarest subtype of plasma cell neoplasms and is known for its poor prognosis and high incidence of t(11;14). However, t(11;14) has been classified as a standard-risk rather than high-risk cytogenetic abnormality in multiple myeloma. We have been unable to explain the discrepancy that the hallmark of IgE plasma cell neoplasm with a poor prognosis is a standard-risk cytogenetic abnormality.
View Article and Find Full Text PDFArticle Synopsis
- Recurrent miscarriage is defined as having three or more first-trimester losses, but clinicians can investigate after two if they suspect underlying issues.
- Women experiencing recurrent miscarriage should be tested for certain blood clotting disorders and offered assessments like 3D ultrasounds for uterine anomalies.
- Routine testing for certain inherited conditions is not recommended, and lifestyle changes like maintaining a healthy BMI, quitting smoking, and limiting alcohol and caffeine intake are advised.
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Cancers (Basel)
June 2023
Hematology Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
Cytogenetic assessment in myelofibrosis is essential for risk stratification and patient management. However, an informative karyotype is unavailable in a significant proportion of patients. Optical genome mapping (OGM) is a promising technique that allows for a high-resolution assessment of chromosomal aberrations (structural variants, copy number variants, and loss of heterozygosity) in a single workflow.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!